Skip to main content
. 2022 Jan 13;12:807869. doi: 10.3389/fpsyg.2021.807869

Table 1.

Study characteristics.

Study Design Data collection (Months) Sample size Type of participants Gender (% Women) Age in years (SD) Pathologies (%) Quality STROBE/CONSORT
1. Sheridan et al. (2021) ROS 12 963 P 43 75.8
(NI)
Cancer: 100 20
2. Cai et al. (2020) POS 26 290 P, CG P: 53.8 P: 72.4 (12.38) Cancer: 100 21
CG: 67.2 CG: 59.3 (13.10)
3. Skorstengaard et al. (2020) RCT 36 N: 205 P 50 69 (NI) Cancer: 50.1 21
n (intervention) 102 Heart disease: 16.7
n (control): 103 Lung disease: 33.2
4. Ali et al. (2019) ROS 60 2176 P NI NI Cancer: 88 18
Non-cancer: 22
5. Blanchard et al. (2019) ROS 22 191 P 55.5 57.6 (13.26) Cancer: 100 19
6. Wiggins et al. (2019) ROS 16 1047 P 64.6 <79 (DT 13.8) Cancer: 10.0 19
Cardiac disease: 4.4
Vascular disease: 2.2
Respiratory disease: 1.7
Neurological disease: 1.6
Dementia: 75.8
Other: 4.3
7. Bannon et al. (2018) ROS 6 467 (363 included in the analysis) P 60.6 <69 (57.5%) Cancer: 100 18
8. Chiba et al. (2018) Mixed 12 18 P/CG P, CG, GP P: 11.2 P: 71.9 (12.4) Cancer: 100 18
24 GP CG: 94.4 CG: 61.9 (12.9)
GP: 16.7 GP: NI
9. Raijmakers et al. (2018) ROS 17 797 P P: 53.6 P <65 57.6% Cancer: 43.7 19
CG: 69.3 CG <75 27.2% Stroke: 12.4
COPD: 10.9
Heart failure: 14.6
Dementia: 26.5
10. Higginson et al. (2017) POS 17 138 P 49 74 (NI) Cancer: 88.0 18
Non-cancer: 12.0
11. Lin et al. (2017) ROS 55 481 P 39.3 70.6 (14.3) Cancer: 70.9 21
Non-cancer: 29.1
12. Howell et al. (2017) ROS 36 323 P 44.9 72.4 (12.7) Cancer (haematological): 100 21
13. de Graaf et al. (2016) ROS 6 130 P 52 72 (12.1) Cancer: 89 21
Lung failure, COPD: 3
Renal failure: 1
ALS: 2
Heart failure: 1
Dementia: 1
Other: 2
14. Arnold et al. (2015) ROS 12 1127 P 50 70 (13) Cancer: 94 15
Other: 6
15. Burge et al. (2015) ROS 24 1316 (605 included in the analysis) P 51.3 79.1 (12.8) Cancer: 38.1
Others: 61.9
21
16. Gage et al. (2015) ROS 18 688 P 43.6 75.10 (NI) NI 18
17. Ko et al. (2014) ROS 36 695 P 43,3 ≥ 65: 67.9% Cancer: 100 19
18. Hunt et al. (2014) ROS 7 1422 P, CG P: 34.6 P: ≥ 60: 91.8% Cancer: 34.6 20
CG: 64.9 CG: ≥ 60: 55.5% Cardiovascular disease: 24.9
Other: 40.5
19. Aoun and Skett (2013) POS 18 43 (36 included in the analysis) P 49 74 (10.1) Cancer: 100 20
20. Brogaard et al. (2013) POS 21 96 P 41.7 69.9 (NI) Cancer: 100 20
21. Fischer et al. (2013) POS 29 458 P 35 57.9 (14.8) Cancer: 11 18
Other: 89
22. Janssen et al. (2013) POS 24 265 (206 included in the analysis) P 35.9 67.2 (13.1) COPD: 41.8 21
Chronic heart failure: 29.6
Chronic renal failure: 28.6
23. Capel et al. (2012) POS 24 788 P NI NI Cancer: 93 21
Non-cancer: 7
24. Johnson et al. (2012) POS 15 126 (80 included in the analysis) P 38 78 (10.7) Chronic heart failure: 100 21
25. Abarshi et al. (2011) ROS 12 252 (165 included in the analysis) P 55 > 65: 80% Cancer: 38 20
Non-cancer: 62
26. Alonso-Babarro et al. (2011) POS 36 380 (228 included in the analysis) P, CG P: 39.5 P: 66.76 (13.4) Cancer: 100 20
CG: 17.9 CG: 54,32 (14.4)
27. Escobar Pinzon et al. (2011) CS 4 1378 P, CG P:55.6 P: 77.6 (13.2) Cancer: 24.2 21
CG: 63.4 CG: 58.8 (12.8) Dementia: 8.9
Cardiovascular disease: 8.4
Other: 12.0
Multimorbidity: 36.6
Missing/I don't know: 9.9
28. Gerrard et al. (2011) ROS 2007: 6 n (2007): 236 P 2007: 50.5 2007: 78 (NI) 2007: Cancer: 66 20
2009: 6 n (2009): 275 Other: 34
Total: 511 2009: 42.0 2009: 72 (NI) 2009: Cancer: 76
Other: 24
29. Walker et al. (2011) ROS 24 150 P NI NI NI 19
30. Holdsworth and Fisher (2010) ROS 6 298 P NI NI Cancer: 80 18
Other: 20

RCT, randomised controlled trial; ROS, retrospective observational study; POS, prospective observational study; CS, cross-sectional study; COPD, chronic obstructive pulmonary disease; ALS, amyotrophic lateral sclerosis; NI, no information; RRS, rapid response service; P, patient; CG, caregivers; GP, general practitioners.